Sage gets big bump on postpartum depression data

Sage Therapeutics Inc. (NASDAQ:SAGE) jumped $12.56 (37%) to $46.21 on Tuesday, adding more than $400 million in market cap, after it said SAGE-547 met the primary endpoint in a Phase II study to treat severe postpartum depression. The compound is a positive allosteric modulator (PAM) of GABA A receptor.

A continuous infusion of SAGE-547 significantly reduced mean Hamilton Depression Rating (HAM-D) scores from baseline to 60 hours vs. placebo, with a difference greater than 12 points between the groups (p=0.008). The company said the difference "was maintained at similar magnitude" through 30 days of follow-up (p=0.01). ...